Masimo Corporation (MASI) - Stock Analysis
Last updated: Apr 11, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Definitive $180 cash takeover by Danaher announced 2026-02-17 created a large premium and sharp momentum; stock trades below the deal price with near-term catalysts (2/26 earnings call, evolving shareholder litigation) driving an attractive event-arbitrage spread over the next few days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross margins ⢠Positive cash generation ⢠Elevated leverage MASI shows strong unit economics and recent cash/profit recovery but is weighed down by a large FY operating loss, meaningful leverage and a premium market valuation.
Price Behavior
Key Price Behavior Insights: ⢠Tight range ⢠Support defended ⢠Resistance capped Support Level: $175.35â$175.50 Resistance Level: $178.6â$178.7 Over the last month MASI traded in a tight, mildly bullish rangeâup ~1.6% from ~$175.50 to $178.32âsupported near $175.35â$175.50 and capped at $178.6â$178.7, with low volatility favoring range trading unless a volume-driven breakout occurs.
Sentiment & News
Key News Insights: ⢠Deal valuation ⢠Legal scrutiny ⢠Institutional flows Masimo's proposed ~$9.9B sale to Danaher at $180/share is drawing investor activism and legal scrutiny amid heavy institutional repositioning.
AI Summary
Masimo has effectively become an event-driven takeover playâDanaher's $180 cash bid and active shareholder litigation mean nearâterm returns are dominated by deal execution/arbitrage risks (litigation outcomes, tariff-driven margin pressure, and material leverage) rather than its standalone AI/wearables growth thesis.
Description
Masimo designs and manufactures noninvasive physiological monitoring devices and hospital automation software sold worldwide. Its clinical product set includes advanced pulse oximetry that addresses motion and low-perfusion limits of conventional oximeters, a multi-parameter platform for hemoglobin species and oxygen-related metrics, EEG-based brain function monitoring, capnography and gas analyzers, regional oximetry and hemodynamic tools, as well as connectivity and hospital surveillance solutions. The company sells through direct sales, distributors and OEM partners to hospitals, emergency and home care providers, long-term care facilities, physician offices, veterinarians and consumers; it was founded in 1989 and is headquartered in Irvine, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 19 | Feb 26 | MASI | Masimo Corporation | Definitive $180 cash takeover by Danaher announced 2026-02-17 created a large premium and sharp momentum; stock trades below the deal price with near-term catalysts (2/26 earnings call, evolving shareholder litigation) driving an attractive event-arbitrage spread over the next few days. | Closed | -0.1% |
| Nov 17 | Nov 24 | MASI | Masimo Corporation | Q3 2025 earnings beat with strong margin expansion, increased free cash flow, positive patent infringement ruling, extended FDA clearances, and constructive technical trends near moving averages underpin Masimo as a near-term growth opportunity. | Closed | -1.0% |